Rabia Z Mayer1*, George Ansstas2 and Milan J Anadkat1
1Division of Dermatology, Washington University School of Medicine, USA
2Division of Oncology, Washington University School of Medicine, USA
The prognosis for advanced and metastatic malignancies has been significantly altered due to the use of check point inhibitors. Due to the activation of CD4+/CD8+ cytotoxic T-cells, these drugs have a unique spectrum of adverse effects, of which cutaneous manifestations are the most common.
This case report describes the first instance of pembrolizumab-induced neutrophilic dermatosis of the dorsal hands, a rare and localized variant of Sweet’s syndrome in a patient being treated for metastatic melanoma.
Mayer RZ, Ansstas G, Anadkat MJ. Pembrolizumab-Induced Neutrophilic Dermatosis of the Dorsal Hands. Oncol Case Report J. 2020;3(2):1024..